Engineered donor cells aim to shield transplant patients from dangerous viruses

NCT ID NCT07672964

Not yet recruiting Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial tests whether giving patients a special type of donor immune cell, called CD45RA-depleted DLI, can prevent serious viral infections after a stem cell transplant. The study includes 30 high-risk patients who have received a transplant for blood cancer. Researchers will monitor for infections like CMV and EBV, and check how well the immune system recovers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD45RA-depleted donor lymphocyte infusion
What this could lead to: If it works, this approach could reduce the risk of life-threatening viral infections after stem cell transplants, improving survival and recovery.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The treatment itself may cause side effects like graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAPLO-IDENTICAL HCT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm viral infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAPLO-IDENTICAL HCT HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

Ruijin Hospital

Shanghai, SH, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.